Kevin S. J. Thompson
YOU?
Author Swipe
View article: Pharmacologically induced weight loss is associated with distinct gut microbiome changes in obese rats
Pharmacologically induced weight loss is associated with distinct gut microbiome changes in obese rats Open
Background Obesity, metabolic disease and some psychiatric conditions are associated with changes to relative abundance of bacterial species and specific genes in the faecal microbiome. Little is known about the impact of pharmacologically…
View article: Pharmacologically Induced Weight Loss Is Associated With Distinct Gut Microbiome Changes In Obese Rats
Pharmacologically Induced Weight Loss Is Associated With Distinct Gut Microbiome Changes In Obese Rats Open
Background: Obesity, metabolic disease and some psychiatric conditions are associated with changes to relative abundance of bacterial species and specific genes in the fecal microbiome. Little is known about the impact of pharmacologically…
View article: Pharmacologically induced weight loss is associated with distinct gut microbiome changes in obese rats
Pharmacologically induced weight loss is associated with distinct gut microbiome changes in obese rats Open
Background: Obesity, metabolic disease and some psychiatric conditions are associated with changes to relative abundance of bacterial species and specific genes in the fecal microbiome. Little is known about the impact of pharmacologically…
View article: Pharmacologically induced weight loss is associated with distinct gut microbiome changes in obese rats
Pharmacologically induced weight loss is associated with distinct gut microbiome changes in obese rats Open
Background Obesity, metabolic disease and some psychiatric conditions are associated with changes to relative abundance of bacterial species and specific genes in the fecal microbiome. Little is known about the impact of pharmacologically …
View article: Using Esterase Selectivity to Determine the <i>In Vivo</i> Duration of Systemic Availability and Abolish Systemic Side Effects of Topical β-Blockers
Using Esterase Selectivity to Determine the <i>In Vivo</i> Duration of Systemic Availability and Abolish Systemic Side Effects of Topical β-Blockers Open
For disorders of the skin, eyes, ears, and respiratory tract, topical drugs, delivered directly to the target organ, are a therapeutic option. Compared with systemic oral therapy, the benefits of topical treatments include a faster onset o…
View article: Synergetic Learning Model: The Sum is Greater
Synergetic Learning Model: The Sum is Greater Open
Instructional design models provide process insight that guides learning solution designers in their work to meet learning objectives and improve performance. Human resource development scholars often focus on individual learning component…
View article: Novel selective β <sub>1</sub> ‐adrenoceptor antagonists for concomitant cardiovascular and respiratory disease
Novel selective β <sub>1</sub> ‐adrenoceptor antagonists for concomitant cardiovascular and respiratory disease Open
β‐Blockers reduce mortality and improve symptoms in people with heart disease; however, current clinically available β‐blockers have poor selectivity for the cardiac β 1 ‐adrenoceptor (AR) over the lung β 2 ‐AR. Unwanted β 2 blockade risks…